vs

Side-by-side financial comparison of Alector, Inc. (ALEC) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

REPLIGEN CORP is the larger business by last-quarter revenue ($197.9M vs $6.2M, roughly 31.7× Alector, Inc.). REPLIGEN CORP runs the higher net margin — 6.7% vs -597.5%, a 604.2% gap on every dollar of revenue. On growth, REPLIGEN CORP posted the faster year-over-year revenue change (13.6% vs -88.5%). Over the past eight quarters, REPLIGEN CORP's revenue compounded faster (14.4% CAGR vs -37.4%).

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for neurodegenerative diseases. Its product pipeline targets unmet medical needs including Alzheimer’s disease, frontotemporal dementia, and Parkinson’s disease, and it collaborates with global pharmaceutical partners to advance candidate therapies through clinical trials.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

ALEC vs RGEN — Head-to-Head

Bigger by revenue
RGEN
RGEN
31.7× larger
RGEN
$197.9M
$6.2M
ALEC
Growing faster (revenue YoY)
RGEN
RGEN
+102.1% gap
RGEN
13.6%
-88.5%
ALEC
Higher net margin
RGEN
RGEN
604.2% more per $
RGEN
6.7%
-597.5%
ALEC
Faster 2-yr revenue CAGR
RGEN
RGEN
Annualised
RGEN
14.4%
-37.4%
ALEC

Income Statement — Q4 2025 vs Q4 2025

Metric
ALEC
ALEC
RGEN
RGEN
Revenue
$6.2M
$197.9M
Net Profit
$-37.3M
$13.3M
Gross Margin
52.5%
Operating Margin
-634.4%
9.0%
Net Margin
-597.5%
6.7%
Revenue YoY
-88.5%
13.6%
Net Profit YoY
-1696.9%
143.9%
EPS (diluted)
$-0.34
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALEC
ALEC
RGEN
RGEN
Q4 25
$6.2M
$197.9M
Q3 25
$3.3M
$188.8M
Q2 25
$7.9M
$182.4M
Q1 25
$3.7M
$169.2M
Q4 24
$54.2M
$174.1M
Q3 24
$15.3M
$154.9M
Q2 24
$15.1M
$154.1M
Q1 24
$15.9M
$151.3M
Net Profit
ALEC
ALEC
RGEN
RGEN
Q4 25
$-37.3M
$13.3M
Q3 25
$-34.7M
$14.9M
Q2 25
$-30.5M
$14.9M
Q1 25
$-40.5M
$5.8M
Q4 24
$-2.1M
$-30.3M
Q3 24
$-42.2M
$-654.0K
Q2 24
$-38.7M
$3.3M
Q1 24
$-36.1M
$2.1M
Gross Margin
ALEC
ALEC
RGEN
RGEN
Q4 25
52.5%
Q3 25
53.2%
Q2 25
50.0%
Q1 25
53.6%
Q4 24
26.1%
Q3 24
50.0%
Q2 24
49.8%
Q1 24
49.5%
Operating Margin
ALEC
ALEC
RGEN
RGEN
Q4 25
-634.4%
9.0%
Q3 25
-1153.6%
8.9%
Q2 25
-433.6%
7.6%
Q1 25
-1216.5%
3.9%
Q4 24
-13.4%
-17.7%
Q3 24
-315.7%
-5.1%
Q2 24
-302.4%
1.0%
Q1 24
-275.0%
1.3%
Net Margin
ALEC
ALEC
RGEN
RGEN
Q4 25
-597.5%
6.7%
Q3 25
-1063.4%
7.9%
Q2 25
-387.7%
8.2%
Q1 25
-1101.6%
3.4%
Q4 24
-3.8%
-17.4%
Q3 24
-275.2%
-0.4%
Q2 24
-256.4%
2.2%
Q1 24
-227.0%
1.4%
EPS (diluted)
ALEC
ALEC
RGEN
RGEN
Q4 25
$-0.34
$0.24
Q3 25
$-0.34
$0.26
Q2 25
$-0.30
$0.26
Q1 25
$-0.41
$0.10
Q4 24
$-0.02
$-0.55
Q3 24
$-0.43
$-0.01
Q2 24
$-0.40
$0.06
Q1 24
$-0.38
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALEC
ALEC
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$256.0M
$767.6M
Total DebtLower is stronger
$10.0M
$542.2M
Stockholders' EquityBook value
$30.6M
$2.1B
Total Assets
$293.2M
$2.9B
Debt / EquityLower = less leverage
0.33×
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALEC
ALEC
RGEN
RGEN
Q4 25
$256.0M
$767.6M
Q3 25
$291.1M
$748.7M
Q2 25
$307.3M
$708.9M
Q1 25
$354.6M
$697.2M
Q4 24
$413.4M
$757.4M
Q3 24
$457.2M
$784.0M
Q2 24
$503.3M
$809.1M
Q1 24
$562.1M
$780.6M
Total Debt
ALEC
ALEC
RGEN
RGEN
Q4 25
$10.0M
$542.2M
Q3 25
$537.9M
Q2 25
Q1 25
Q4 24
$10.0M
$525.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ALEC
ALEC
RGEN
RGEN
Q4 25
$30.6M
$2.1B
Q3 25
$57.7M
$2.1B
Q2 25
$71.2M
$2.1B
Q1 25
$94.6M
$2.0B
Q4 24
$126.8M
$2.0B
Q3 24
$118.9M
$2.0B
Q2 24
$150.6M
$2.0B
Q1 24
$178.9M
$2.0B
Total Assets
ALEC
ALEC
RGEN
RGEN
Q4 25
$293.2M
$2.9B
Q3 25
$335.3M
$2.9B
Q2 25
$356.4M
$2.9B
Q1 25
$408.3M
$2.9B
Q4 24
$468.3M
$2.8B
Q3 24
$516.0M
$2.8B
Q2 24
$570.7M
$2.9B
Q1 24
$635.5M
$2.8B
Debt / Equity
ALEC
ALEC
RGEN
RGEN
Q4 25
0.33×
0.26×
Q3 25
0.26×
Q2 25
Q1 25
Q4 24
0.08×
0.27×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALEC
ALEC
RGEN
RGEN
Operating Cash FlowLast quarter
$-41.7M
$25.7M
Free Cash FlowOCF − Capex
$17.6M
FCF MarginFCF / Revenue
8.9%
Capex IntensityCapex / Revenue
0.0%
4.1%
Cash ConversionOCF / Net Profit
1.93×
TTM Free Cash FlowTrailing 4 quarters
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALEC
ALEC
RGEN
RGEN
Q4 25
$-41.7M
$25.7M
Q3 25
$-32.5M
$48.1M
Q2 25
$-49.0M
$28.6M
Q1 25
$-60.8M
$15.0M
Q4 24
$-55.0M
$39.2M
Q3 24
$-50.7M
$49.3M
Q2 24
$-62.8M
$42.2M
Q1 24
$-61.3M
$44.7M
Free Cash Flow
ALEC
ALEC
RGEN
RGEN
Q4 25
$17.6M
Q3 25
$-32.5M
$43.4M
Q2 25
$-49.1M
$21.5M
Q1 25
$-60.8M
$11.4M
Q4 24
$-55.2M
$33.6M
Q3 24
$-50.9M
$42.3M
Q2 24
$-63.1M
$37.4M
Q1 24
$-61.9M
$36.4M
FCF Margin
ALEC
ALEC
RGEN
RGEN
Q4 25
8.9%
Q3 25
-997.6%
23.0%
Q2 25
-623.0%
11.8%
Q1 25
-1655.0%
6.8%
Q4 24
-101.8%
19.3%
Q3 24
-332.1%
27.3%
Q2 24
-418.6%
24.3%
Q1 24
-389.3%
24.0%
Capex Intensity
ALEC
ALEC
RGEN
RGEN
Q4 25
0.0%
4.1%
Q3 25
0.3%
2.5%
Q2 25
0.1%
3.9%
Q1 25
0.5%
2.1%
Q4 24
0.3%
3.2%
Q3 24
1.4%
4.5%
Q2 24
2.2%
3.1%
Q1 24
3.4%
5.5%
Cash Conversion
ALEC
ALEC
RGEN
RGEN
Q4 25
1.93×
Q3 25
3.23×
Q2 25
1.92×
Q1 25
2.57×
Q4 24
Q3 24
Q2 24
12.70×
Q1 24
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons